polatuzumab vedotin

Home
Ligands
polatuzumab vedotin

GtoPdb Ligand ID: 8404

Synonyms: ACD79B-VCMMAE | polatuzumab vedotin-piiq | Polivy® | RG-7596 | RG7596 | RO5541077-000

polatuzumab vedotin is an approved drug (FDA (2019), EMA (2020))

Comment: Polatuzumab vedotin is an antibody drug conjugate containing an anti-CD79b monoclonal antibody linked to the toxin monomethyl auristatin E (MMAE, aka vedotin; PubChem CID 11542188).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence matches identify US8088378 as the claiming patent [1].

Immunopharmacology Comments
This antibody is included in Guide To IMMUNOPHARMACOLOGY as it is used to treat B cell cancer. Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). CD79b is one of the signalling components of the B-cell receptor (the other being CD79a) and it is expressed exclusively by B cells. Polatuzumab delivers the microtubule-disrupting and antimitotic conjugate (vedotin a.k.a. monomethyl auristatin E) to lymphoma cells. It has previously been reported that targeting CD79b using an ADC was more effective against non-Hodgkin lymphoma cells than was targeting CD79a [3].

Immunopharmacology Comments

This antibody is included in Guide To IMMUNOPHARMACOLOGY as it is used to treat B cell cancer. Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). CD79b is one of the signalling components of the B-cell receptor (the other being CD79a) and it is expressed exclusively by B cells. Polatuzumab delivers the microtubule-disrupting and antimitotic conjugate (vedotin a.k.a. monomethyl auristatin E) to lymphoma cells. It has previously been reported that targeting CD79b using an ADC was more effective against non-Hodgkin lymphoma cells than was targeting CD79a [3].